{"title_page": "ELB-139", "text_new": "{{Drugbox\n| verifiedrevid = 451925233\n| IUPAC_name = 1-(4-Chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-one\n| image = ELB-139.png\n\n<!--Clinical data-->\n| tradename =  \n| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US = <!-- A / B            / C / D / X -->\n| pregnancy_category =  \n| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->\n| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->\n| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->\n| legal_status =  \n| routes_of_administration =\n\n<!--Pharmacokinetic data-->\n| bioavailability =  \n| protein_bound =  \n| metabolism =  \n| elimination_half-life =  \n| excretion =\n\n<!--Identifiers-->\n| CAS_number_Ref = {{cascite|correct|??}}\n| CAS_number = 188116-08-7\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = BKP2A5554F\n| ATC_prefix =  \n| ATC_suffix =  \n| PubChem = 11277418\n| DrugBank_Ref = {{drugbankcite|correct|drugbank}}\n| DrugBank =  \n|  ChemSpiderID = 9452418\n\n<!--Chemical data-->\n| C=14 | H=16 | Cl=1 | N=3 | O=1 \n| molecular_weight = 277.749 g/mol\n| smiles = Clc3ccc(cc3)N1CC(=NC1=O)N2CCCCC2\n|  StdInChI = 1S/C14H16ClN3O/c15-11-4-6-12(7-5-11)18-10-13(16-14(18)19)17-8-2-1-3-9-17/h4-7H,1-3,8-10H2\n|  StdInChIKey = YGXIELIREXEJQN-UHFFFAOYSA-N\n\n}}\n\n'''ELB-139''' ('''LS-191,811''') is an [[anxiolytic]] drug with a novel chemical structure, which is used in scientific research. It has similar effects to [[benzodiazepine]] drugs, but is structurally distinct and so is classed as a [[nonbenzodiazepine]] anxiolytic.<ref>{{cite journal | vauthors = Langen B, Egerland U, Bern\u00f6ster K, Dost R, Unverferth K, Rundfeldt C | title = Characterization in rats of the anxiolytic potential of ELB139 [1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-on], a new agonist at the benzodiazepine binding site of the GABAA receptor | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 314 | issue = 2 | pages = 717\u201324 | date = August 2005 | pmid = 15860576 | doi = 10.1124/jpet.105.084681 }}</ref><ref>{{cite journal | vauthors = Atack JR | title = The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics | journal = Expert Opinion on Investigational Drugs | volume = 14 | issue = 5 | pages = 601\u201318 | date = May 2005 | pmid = 15926867 | doi = 10.1517/13543784.14.5.601 }}</ref>\n\nELB-139 is a subtype-selective [[partial agonist]] at [[GABA A receptor|GABA<sub>A</sub> receptor]]s, with highest [[Dissociation constant#Protein-ligand binding|affinity]] for the \u03b13 subtype, but highest [[Efficacy#Pharmacology|efficacy]] at \u03b11 and \u03b12.<ref>{{cite journal | vauthors = Rabe H, Kronbach C, Rundfeldt C, L\u00fcddens H | title = The novel anxiolytic ELB139 displays selectivity to recombinant GABA(A) receptors different from diazepam | journal = Neuropharmacology | volume = 52 | issue = 3 | pages = 796\u2013801 | date = March 2007 | pmid = 17087982 | doi = 10.1016/j.neuropharm.2006.09.013 | url = https://www.semanticscholar.org/paper/383bf665628fc877b4d8e251040a137fdb5daf5a }}</ref> It has primarily [[anxiolytic]] and [[anticonvulsant]] effects, but produces little [[sedative]] effects or [[ataxia]],<ref>{{cite journal | vauthors = Grunwald C, Rundfeldt C, Lankau HJ, Arnold T, H\u00f6fgen N, Dost R, Egerland U, Hofmann HJ, Unverferth K | display-authors = 6 | title = Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors | journal = Journal of Medicinal Chemistry | volume = 49 | issue = 6 | pages = 1855\u201366 | date = March 2006 | pmid = 16539371 | doi = 10.1021/jm0509400 }}</ref> and has also been demonstrated in rats to increase [[serotonin]] levels in the [[striatum]] and [[prefrontal cortex]], without affecting [[dopamine]] levels.<ref>{{cite journal | vauthors = Langen B, Rundfeldt C | title = ELB139 an agonist at the benzodiazepine binding site increases 5-HT in the striatum and prefrontal cortex of rats: a microdialysis study | journal = Pharmacology, Biochemistry, and Behavior | volume = 86 | issue = 1 | pages = 79\u201385 | date = January 2007 | pmid = 17257662 | doi = 10.1016/j.pbb.2006.12.010 | url = https://www.semanticscholar.org/paper/51df4da0ef343c5ed68ee89e9d7c8be6af5fff60 }}</ref> It has been proposed as a possible candidate for a novel non-sedating anxiolytic or anticonvulsant drug for use in humans<ref>{{cite journal | vauthors = Rogawski MA | title = Diverse mechanisms of antiepileptic drugs in the development pipeline | journal = Epilepsy Research | volume = 69 | issue = 3 | pages = 273\u201394 | date = June 2006 | pmid = 16621450 | pmc = 1562526 | doi = 10.1016/j.eplepsyres.2006.02.004 }}</ref> The sponsor elbion AG registered a clinical trial in  [http://clinicaltrials.gov/ct2/show/study/NCT00322803 ClinicalTrials.gov]\nfor the treatment of anxiety associated with panic disorder but the results have not been reported.<ref>{{cite journal | vauthors = Whiting PJ | title = GABA-A receptors: a viable target for novel anxiolytics? | journal = Current Opinion in Pharmacology | volume = 6 | issue = 1 | pages = 24\u20139 | date = February 2006 | pmid = 16359919 | doi = 10.1016/j.coph.2005.08.005 }}</ref> It was developed by Arzneimittelwerk Dresden in the 1990s.<ref>{{cite patent | country = US | number = 5869481 | title = Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making }}</ref>\n\n== References ==\n<references />\n\n{{Anxiolytics}}\n{{GABAAR PAMs}}\n\n[[Category:Anxiolytics]]\n[[Category:Chloroarenes]]\n[[Category:Imidazolines]]\n[[Category:Ureas]]\n[[Category:Lactams]]\n[[Category:Piperidines]]\n[[Category:GABAA receptor positive allosteric modulators]]\n\n{{Anxiolytic-stub}}\n", "text_old": "{{Drugbox\n| verifiedrevid = 451925233\n| IUPAC_name = 1-(4-Chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-one\n| image = ELB-139.png\n\n<!--Clinical data-->\n| tradename =  \n| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US = <!-- A / B            / C / D / X -->\n| pregnancy_category =  \n| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->\n| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->\n| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->\n| legal_status =  \n| routes_of_administration =\n\n<!--Pharmacokinetic data-->\n| bioavailability =  \n| protein_bound =  \n| metabolism =  \n| elimination_half-life =  \n| excretion =\n\n<!--Identifiers-->\n| CAS_number_Ref = {{cascite|correct|??}}\n| CAS_number = 188116-08-7\n| ATC_prefix =  \n| ATC_suffix =  \n| PubChem = 11277418\n| DrugBank_Ref = {{drugbankcite|correct|drugbank}}\n| DrugBank =  \n|  ChemSpiderID = 9452418\n\n<!--Chemical data-->\n| C=14 | H=16 | Cl=1 | N=3 | O=1 \n| molecular_weight = 277.749 g/mol\n| smiles = Clc3ccc(cc3)N1CC(=NC1=O)N2CCCCC2\n|  StdInChI = 1S/C14H16ClN3O/c15-11-4-6-12(7-5-11)18-10-13(16-14(18)19)17-8-2-1-3-9-17/h4-7H,1-3,8-10H2\n|  StdInChIKey = YGXIELIREXEJQN-UHFFFAOYSA-N\n\n}}\n\n'''ELB-139''' ('''LS-191,811''') is an [[anxiolytic]] drug with a novel chemical structure, which is used in scientific research. It has similar effects to [[benzodiazepine]] drugs, but is structurally distinct and so is classed as a [[nonbenzodiazepine]] anxiolytic.<ref>{{cite journal | vauthors = Langen B, Egerland U, Bern\u00f6ster K, Dost R, Unverferth K, Rundfeldt C | title = Characterization in rats of the anxiolytic potential of ELB139 [1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-on], a new agonist at the benzodiazepine binding site of the GABAA receptor | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 314 | issue = 2 | pages = 717\u201324 | date = August 2005 | pmid = 15860576 | doi = 10.1124/jpet.105.084681 }}</ref><ref>{{cite journal | vauthors = Atack JR | title = The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics | journal = Expert Opinion on Investigational Drugs | volume = 14 | issue = 5 | pages = 601\u201318 | date = May 2005 | pmid = 15926867 | doi = 10.1517/13543784.14.5.601 }}</ref>\n\nELB-139 is a subtype-selective [[partial agonist]] at [[GABA A receptor|GABA<sub>A</sub> receptor]]s, with highest [[Dissociation constant#Protein-ligand binding|affinity]] for the \u03b13 subtype, but highest [[Efficacy#Pharmacology|efficacy]] at \u03b11 and \u03b12.<ref>{{cite journal | vauthors = Rabe H, Kronbach C, Rundfeldt C, L\u00fcddens H | title = The novel anxiolytic ELB139 displays selectivity to recombinant GABA(A) receptors different from diazepam | journal = Neuropharmacology | volume = 52 | issue = 3 | pages = 796\u2013801 | date = March 2007 | pmid = 17087982 | doi = 10.1016/j.neuropharm.2006.09.013 | url = https://www.semanticscholar.org/paper/383bf665628fc877b4d8e251040a137fdb5daf5a }}</ref> It has primarily [[anxiolytic]] and [[anticonvulsant]] effects, but produces little [[sedative]] effects or [[ataxia]],<ref>{{cite journal | vauthors = Grunwald C, Rundfeldt C, Lankau HJ, Arnold T, H\u00f6fgen N, Dost R, Egerland U, Hofmann HJ, Unverferth K | display-authors = 6 | title = Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors | journal = Journal of Medicinal Chemistry | volume = 49 | issue = 6 | pages = 1855\u201366 | date = March 2006 | pmid = 16539371 | doi = 10.1021/jm0509400 }}</ref> and has also been demonstrated in rats to increase [[serotonin]] levels in the [[striatum]] and [[prefrontal cortex]], without affecting [[dopamine]] levels.<ref>{{cite journal | vauthors = Langen B, Rundfeldt C | title = ELB139 an agonist at the benzodiazepine binding site increases 5-HT in the striatum and prefrontal cortex of rats: a microdialysis study | journal = Pharmacology, Biochemistry, and Behavior | volume = 86 | issue = 1 | pages = 79\u201385 | date = January 2007 | pmid = 17257662 | doi = 10.1016/j.pbb.2006.12.010 | url = https://www.semanticscholar.org/paper/51df4da0ef343c5ed68ee89e9d7c8be6af5fff60 }}</ref> It has been proposed as a possible candidate for a novel non-sedating anxiolytic or anticonvulsant drug for use in humans<ref>{{cite journal | vauthors = Rogawski MA | title = Diverse mechanisms of antiepileptic drugs in the development pipeline | journal = Epilepsy Research | volume = 69 | issue = 3 | pages = 273\u201394 | date = June 2006 | pmid = 16621450 | pmc = 1562526 | doi = 10.1016/j.eplepsyres.2006.02.004 }}</ref> The sponsor elbion AG registered a clinical trial in  [http://clinicaltrials.gov/ct2/show/study/NCT00322803 ClinicalTrials.gov]\nfor the treatment of anxiety associated with panic disorder but the results have not been reported.<ref>{{cite journal | vauthors = Whiting PJ | title = GABA-A receptors: a viable target for novel anxiolytics? | journal = Current Opinion in Pharmacology | volume = 6 | issue = 1 | pages = 24\u20139 | date = February 2006 | pmid = 16359919 | doi = 10.1016/j.coph.2005.08.005 }}</ref> It was developed by Arzneimittelwerk Dresden in the 1990s.<ref>{{cite patent | country = US | number = 5869481 | title = Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making }}</ref>\n\n== References ==\n<references />\n\n{{Anxiolytics}}\n{{GABAAR PAMs}}\n\n[[Category:Anxiolytics]]\n[[Category:Chloroarenes]]\n[[Category:Imidazolines]]\n[[Category:Ureas]]\n[[Category:Lactams]]\n[[Category:Piperidines]]\n[[Category:GABAA receptor positive allosteric modulators]]\n\n{{Anxiolytic-stub}}\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/ELB-139"}
